/

Cassava Sciences, Inc.

SAVA US

SAVA USCassava Sciences, Inc.

United States Composite

22.34

USD

+0.61

(+2.81%)

-2.32EPS Dil.

-9.64P/E

943.57MMarket Cap

Cassava Sciences, Inc.

SAVA

(United States Composite)

Recent

price

22.34

P/E

ratio

-9.64

div

yld

- -

ROIC.AI

Legends:

Stock price

-1.82

Beta (1.0 Market)

% total return 04/29

Stock

S&P500

YTD

-11.71

- -

-56.91

- -

1,730.36

- -

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

TTM

FRC

10.56

3.41

2.76

1.82

1.70

6.39

- -

2.54

-0.58

-1.97

-0.41

-0.54

4.91

-1.92

-2.18

-2.28

-1.82

-0.61

-0.27

-0.24

-0.82

-1.90

-2.32

1.50

-2.44

-0.02

-0.04

-1.12

-1.08

-1.49

-1.43

-1.89

-1.26

-0.45

-0.15

-0.21

-1.33

-2.00

-1.97

- -

-18.98

-19.45

-21.13

-20.68

-20.94

-16.01

-17.81

-19.98

-22.07

-23.86

-9.52

-7.72

-4.96

-5.18

-6.79

-9.01

17.35

17.91

5.37

6.95

2.03

7.43

6.13

4.49

2.83

1.47

1.14

1.01

2.62

6.32

5.44

3.25

- -

13.67

-32.85

-81.52

-30.60

-35.79

76.28

- -

-3

-12

-3

-12

-14

-15

-12

-7

-5

-6

-32

-76

-97

- -

24.08

-16.86

-71.53

-22.75

-31.64

76.71

- -

171

160

232

204

115

- -

104

108

254

228

137

- -

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

- -

LT Borrowings

- -

LT Finance Leases

- -

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

1,028

701

951

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

175

150

130

Cash, Cash Equivalents & STI

168

142

121

Accounts Receivable, Net

- -

Inventories

- -

Total Current Liabilities

Payables & Accruals

ST Debt

- -

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

- -

Net Income, GAAP

-68.95%

-117.98%

-27.63%

Free Cash Flow

-101.84%

-204.60%

-2.50%

Total Cash Common Dividend

- -

Total Equity

42.81%

90.82%

-39.91%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-0.09

-0.13

-0.24

-0.35

-0.82

2022

-0.44

-0.48

-0.51

-0.47

-1.90

2023

-0.58

-0.63

-0.61

-0.50

-2.32

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Business: Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Company News

Yahoo
14 days ago
Redemption Date Announced for Warrants
Yahoo
a month ago
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
Yahoo
2 months ago
Bullish Cassava Sciences Insiders Loaded Up On US$3.12m Of Stock

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

TTM

FRC

10.56

3.41

2.76

1.82

1.70

6.39

- -

2.54

-0.58

-1.97

-0.41

-0.54

4.91

-1.92

-2.18

-2.28

-1.82

-0.61

-0.27

-0.24

-0.82

-1.90

-2.32

1.50

-2.44

-0.02

-0.04

-1.12

-1.08

-1.49

-1.43

-1.89

-1.26

-0.45

-0.15

-0.21

-1.33

-2.00

-1.97

- -

-18.98

-19.45

-21.13

-20.68

-20.94

-16.01

-17.81

-19.98

-22.07

-23.86

-9.52

-7.72

-4.96

-5.18

-6.79

-9.01

17.35

17.91

5.37

6.95

2.03

7.43

6.13

4.49

2.83

1.47

1.14

1.01

2.62

6.32

5.44

3.25

- -

13.67

-32.85

-81.52

-30.60

-35.79

76.28

- -

-3

-12

-3

-12

-14

-15

-12

-7

-5

-6

-32

-76

-97

- -

24.08

-16.86

-71.53

-22.75

-31.64

76.71

- -

171

160

232

204

115

- -

104

108

254

228

137

- -